source
- Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programsEpicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
- FDA issues complete response letter rejecting ITM Isotope's radiopharma therapy over manufacturing concernsFDA sent a complete response letter rejecting the NDA for ITM Isotope's investigational radiopharmaceutical, citing manufacturing and third-party facility issues. The agency said there were no con…